Speaker: Mattias Trost
Matthias Trost studied chemistry in Freiburg, Germany and Manchester, UK. He has a PhD in Cellular Microbiology & Proteomics from the Helmholtz Centre for Infection Research, Braunschweig, Germany and was a postdoctoral fellow with Michel Desjardins at the University of Montreal, Canada and with Pierre Thibault, Institute for Research in Immunology and Cancer, Montreal, Canada. In 2010 he became Program Leader and Head of Proteomics at the MRC Protein Phosphorylation Unit at the University of Dundee, UK.
Since 2016, he is Professor of Proteomics at Newcastle University. Matthias’s research focusses on large-scale proteome and PTM analyses to understand innate immunity in macrophages. He also has a strong interest in drug discovery for which his lab developed high-throughput MALDI TOF mass spectrometry.
In this Webinar Matthias Trost discusses how high-throughput MALDI-TOF mass spectrometry has become an exciting new method for drug discovery. It allows for ultra-fast, label-free screening and has the potential to become the tool of choice for many drug discovery efforts. Matthias discusses the current state of MALDI-TOF mass spectrometry and demonstrates a novel screening method to assay E1-E2-E3 ubiquitin ligase activity and specificity, using high-throughput MALDI-TOF mass spectrometry.
Following this webinar, you will be able to:
- Discuss the current state of MALDI-TOF mass spectrometry
- Explain the importance of ubiquitin ligase
- Describe a novel screening method to assay E1-E2-E3 ubiquitin ligase activity
- Identify the challenges of MALDI-TOF screening assays
- Explain the potential of this new assay
This webinar is a collaboration between Bruker and Division of Pharmacy Professional Development at the University of Wisconsin-Madison’s School of Pharmacy.
For more webinars from our expert series click here.